Dianthus Therapeutics, Inc. /DE/
Dianthus Therapeutics, Inc. /DE/ (DNTH): 5 pipeline candidates · 3 upcoming catalysts · ~100 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
100.0 months
D/E 0.04 · 0% dilution
Lead: Phase 3
5 candidates
3 upcoming, next in ~135d
0 buys · 26 sells (180d)
A transparent, data-derived signal for Dianthus Therapeutics, Inc. /DE/across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.3B
Cash
$627.8M
Quarterly Burn
$28.9M
Runway
100.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| abelacimab | Phase 3 |
| claseprubart | Phase 3 |
| dalteparin | Phase 3 |
| DNTH103 | Phase 3 |
| dnth212 | Phase 3 |
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
240
Total value held
$4.91B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 7,767,686 | $651.9M |
| avidity partners management lp | 4,208,368 | $361.3M |
| vanguard capital management llc | 4,062,498 | $340.9M |
| blackrock, inc. | 3,175,703 | $266.5M |
| ra capital management, l.p. | 2,611,733 | $219.2M |
| wellington management group llp | 2,595,783 | $217.8M |
| citadel advisors llc | 1,648,983 | $138.4M |
| state street corp | 1,398,913 | $117.4M |
| venrock adviser, llc | 1,180,000 | $99.0M |
| fred alger management, llc | 1,161,923 | $97.5M |
Showing top 10 of 240 institutional holders of Dianthus Therapeutics, Inc. /DE/. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Dianthus Therapeutics, Inc. /DE/'s pipeline?
Dianthus Therapeutics, Inc. /DE/ (DNTH) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Dianthus Therapeutics, Inc. /DE/'s lead drug candidate?
Dianthus Therapeutics, Inc. /DE/'s most advanced tracked candidate is abelacimab (Phase 3) for Venous Thromboembolism; Atrial Fibrillation (AF).
What is Dianthus Therapeutics, Inc. /DE/'s next catalyst?
Dianthus Therapeutics, Inc. /DE/'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLua" — expected October 31, 2026.
What is Dianthus Therapeutics, Inc. /DE/'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Dianthus Therapeutics, Inc. /DE/ has approximately 100.0 months of cash runway.
What is Dianthus Therapeutics, Inc. /DE/'s market capitalization?
Dianthus Therapeutics, Inc. /DE/'s market capitalization is approximately $4.3B.
Get the full picture on Dianthus Therapeutics, Inc. /DE/
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.